SCHEMBL435198

SCHEMBL435198

CC1(C)OC(=O)C(=Cc2ccc(O)cc2)C(=O)O1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 2/20 0.71
ALDH1A1 P00352 8/20 0.65
CRHBP P24387 2/20 0.65
CRHR2 Q13324 2/20 0.65
KMT2A Q03164 5/20 0.55
KDM4E B2RXH2 3/20 0.54
METAP1 P53582 1/20 0.53
LMNA P02545 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HPGD P15428 2/20 0.50
RET P07949 1/20 0.49
FLT3 P36888 1/20 0.49
PLK4 O00444 1/20 0.49
PDGFRB P09619 1/20 0.49
PLK1 P53350 1/20 0.49
GAA P10253 1/20 0.49
MAPT P10636 1/20 0.49
MEN1 O00255 3/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21601041 0.84 SIRT1 (1.00) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL17199432 0.83 ALDH1A1 (0.67) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL19569879 0.82 SIRT1 (0.56) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL1587773 0.82 ALDH1A1 (0.66) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL12865971 0.82 ALDH1A1 (0.59) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL12345520 0.81 ALDH1A1 (0.65) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL2074007 0.81 ALDH1A1 (0.65) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL658436 0.81 ALDH1A1 (0.65) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL19551422 0.81 KMT2A (0.59) SIRT1ALDH1A1CRHBPCRHR2KMT2A
SCHEMBL2497792 0.81 KMT2A (0.59) SIRT1ALDH1A1CRHBPCRHR2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11964938-B2 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists CELON PHARMA S.A. (PL) 2024-04-23 US disclosed
EP-3737470-B9 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2024-03-13 EP disclosed
CN-111757770-B 3-Phenyl-4-hexynoic acid derivatives as GPR40 agonists 赛隆制药股份公司 2023-10-03 CN disclosed
US-11731961-B2 Phenyl propionic acid derivatives and uses thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-08-22 US disclosed
US-11731961-B2 Phenyl propionic acid derivatives and uses thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-08-22 US disclosed
US-11731961-B2 Phenyl propionic acid derivatives and uses thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2023-08-22 US disclosed
EP-3555076-B1 NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF IL DONG PHARMA (KR) 2023-04-05 EP disclosed
EP-3737470-B1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2022-12-14 EP disclosed
EP-3737470-B1 3-PHENYL-4-HEXYNOIC ACID DERIVATIVES AS GPR40 AGONISTS Celon Pharma Sa (PL) 2022-12-14 EP disclosed
CN-110049984-B Phenylpropionic acid derivatives and use thereof 日东制药株式会社 2022-11-15 CN disclosed
US-20070066647-A1 Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders AMGEN ING. (US) 2007-03-22 US disclosed
US-20070066647-A1 Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders AMGEN ING. (US) 2007-03-22 US disclosed
US-20070066647-A1 Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders AMGEN ING. (US) 2007-03-22 US disclosed
WO-2007033002-A1 CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2007-03-22 WO disclosed
WO-2007033002-A1 CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS AMGEN INC. (US) 2007-03-22 WO disclosed
EP-1737809-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS Amgen, Inc (US) 2007-01-03 EP disclosed
WO-2006127503-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS AMGEN INC (US) 2006-11-30 WO disclosed
US-20060270724-A1 Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders AMGEN INC (US) 2006-11-30 US disclosed
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders AMGEN INC. 2006-01-05 US disclosed
WO-2005086661-A2 COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR USE IN TREATING METABOLIC DISORDERS AMGEN INC. (US) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004012-A1 Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders PNLIP, IAPP, GPR119 SIRT1 1129/4885ALDH1A1 1567/4885CRHBP 3472/4885
US-20070066647-A1 Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders PC, PNLIP, PDHX SIRT1 1076/4885ALDH1A1 413/4885CRHBP 3212/4885
US-20060270724-A1 Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders IAPP, INSR, GPR119 SIRT1 562/4885ALDH1A1 666/4885CRHBP 2641/4885
US-11964938-B2 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists GPR119, FFAR1, GPR65 SIRT1 1700/4885ALDH1A1 1839/4885CRHBP 1028/4885
US-11731961-B2 Phenyl propionic acid derivatives and uses thereof GPR119, GPR65, GPR55 SIRT1 1489/4885ALDH1A1 731/4885CRHBP 1292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.